On January 7, 2015, a California federal judge granted an FCA defendant’s Motion to Dismiss premised on allegations that it failed to comply with Good Manufacturing Practices (“cGMPs”) regulations. See U.S. ex rel. Campie v. Gilead Sciences, Inc., No. 11-cv-00941 (N.D. Cal. Jan. 7, 2015).
In this case, two former Gilead employees with quality control responsibilities filed a Qui Tam action against their previous employer alleging various violations of cGMP requirements. The relators asserted in their Complaint that they discovered and reported to Gilead officials numerous violations of Federal Food and Drug Administration (“FDA”) regulations, but that Gilead concealed those violations resulting in the sale of misbranded, adulterated drugs. According to relators, each sale of an affected drug was “false” for purposes of FCA liability.
The Court went through each of the relators’ theories and dismissed them. The theories included: (1) using an unregistered manufacturing facility; (2) distributing adulterated drugs; (3) making false statements in New Drug Applications (“NDA”); (4) submitting false certificates of analysis that an active pharmaceutical ingredient was in compliance with cGMPs; and (5) using adulterated drugs in clinical trial products.
The Court noted in its opinion that even when companies make a purported false certification to a regulatory agency such as the FDA, asserting that the company is in compliance with provisions of the FDA Act, that certification cannot in and of itself serve as a basis for an FCA action. Rather, there must be a link between the alleged false statement and the resulting request for payment, namely that the payment must be conditioned on the falsity. Here, the Court did not find the requisite link and granted Gilead’s Motion to Dismiss.
This case can be seen as a step in the right direction in terms of limiting the reach of the FCA and reinforcing that the FCA is not intended to police minor technical and/or regulatory violations unrelated to the contractor’s receipt of federal funding. This case should be cited to by Defendants when faced with an FCA claim based on alleged regulatory non-compliance as it provides additional support and reasoning behind the “Request for Payment” link required before FCA liability should attach.
This blog is provided for general informational purposes only. Because Groff Murphy is a law firm and the authors of this blog’s content are attorneys, the information provided is often legal in nature. An attorney-client relationship is not established by reading this content. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice, and no attorney-client or other relationship is created between you and the author(s), or Groff Murphy or any of its partners, associates or of-counsel. The information is not guaranteed to be correct, complete or up-to-date as information is subject to change and may not be reflected in prior content. The opinions expressed within the blog are the opinions of the author and may not reflect the opinions of Groff Murphy or any other individual attorney at Groff Murphy.
Outcomes: Every legal matter is different, case outcomes are affected by many different variables. No attorney and/or author can guarantee a result in any particular case nor can results be guaranteed based on prior outcomes.